Escitalopram
Drug20 mg target dose for 12 weeks
Other names: Lexapro, 76184942
NCT Number: NCT01728194
This study may help identify how abnormalities in brain systems that control the ability to ignore irrelevant information may contribute to the development of depression in older adults.
Looking for future studies?
Notify Me60 year–85 year
All sexes
Interventional
Phase 4
Weill Cornell Medical College, New York, United States
Approximately half of those who develop depression in late life never had depression before. The classic view is that changes taking place in our brains as we age contribute to the development of late-onset depression. This view is supported by the relative absence of family history for those with late onset depression. This research study will recruit 70 older adults with late life depression and 70 older adults without depression. All participants will receive a sub-clinical, non-contrast (magnetic resonance imaging (MRI) scan at the beginning of the study and then again 12 weeks later at the completion of the study. The depressed older participants will also receive a Food and Drug Administration (FDA)-approved antidepressant, escitalopram (Lexapro), as treatment for their depressive symptoms over 12 weeks. This MRI study may help the researchers identify how abnormalities in brain systems that control our ability to ignore distractions, control our emotions, and anticipate reward may contribute to the development of depression in older adults. The investigators hope that the findings promote the development of tests that may improve the detection of older adults at risk for poor treatment outcomes and eventually guide the development of novel treatments for depression.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
20 mg target dose for 12 weeks
Other names: Lexapro, 76184942
Structural and functional MRI of the brain for research purposes.
Other names: MRI
Time frame: Baseline (Study Entry / Before Tx) and Week 12 (Following Tx)
Depression severity at baseline and week 12 in participants with MDD vs. controls, measured by score on the Montgomery Asberg Depression Rating Scale (MADRS). This measure is a clinical rating of mood with a score range from 0 to 60. Higher scores indicate greater depression severity.
Time frame: Baseline (Study Entry / Before Tx) and Week 12 (Following Tx)
Depression severity at baseline and week 12 in participants with MDD vs. controls, measured by score on the Hamilton Depression Rating Scale (HAM-D). This measure is a clinical rating of mood with a score range from 0 to 76. Higher scores indicate greater depression severity.
Weill Medical College of Cornell University
Other
White Matter and Emotional and Cognitive Control in Late-Onset Depression
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04491045
Behavior, Behavioral Symptoms
Bắc Giang, Vietnam
View Trial DetailsNCT05384704
Behavior, Behavioral Symptoms
Ann Arbor, Michigan, United States
View Trial DetailsNCT05593276
Behavior, Behavioral Symptoms
Ann Arbor, Michigan, United States
View Trial DetailsNCT02861755
Affect, Behavior
Chicago, Illinois, United States
View Trial Details